US FDA approves updated label for Eli Lilly's Kisunla with new dosing in early symptomatic Alzheimer's disease: Indianapolis Thursday, July 10, 2025, 14:00 Hrs [IST] Eli Lilly and ...

Researchers have identified sequential diagnostic patterns that may enhance early detection and improve strategies for disease prevention. Researchers at UCLA Health have uncovered four distinct ...

UCLA's study identifies distinct Alzheimer's disease trajectories, emphasizing the role of shared risk factors in early detection and targeted interventions.

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS, ...

While nursing homes provide essential clinical care, they lack the engagement-based, purpose-driven memory support offered in ...

The drug is Ambroxol. It’s been used for decades to treat respiratory ailments by thinning mucus and easing coughs. But now, ...

The study, which analyzed data on 1.2 million people with dementia, found improvements in five out of eight global regions ...

A person diagnosed with dementia has improved survival outcomes in recent years amid significant progress in dementia ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope.

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

Alzheimer’s disease, which is the most common type of dementia, is on the rise. About 57 million people had dementia worldwide in 2021, and the numbers are escalating. This progressive ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the secret to staving off Alzheimer’s, too.